2024
Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients
Bernabéu-Gimeno M, Pardo-Freire M, Chan B, Turner P, Gil-Brusola A, Pérez-Tarazona S, Carrasco-Hernández L, Quintana-Gallego E, Domingo-Calap P. Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients. Med 2024, 5: 1096-1111.e6. PMID: 38917792, DOI: 10.1016/j.medj.2024.05.017.Peer-Reviewed Original ResearchMulti-drug resistanceCystic fibrosis patientsPhage therapyClinical outcomesLung infectionFibrosis patientsCystic fibrosisPseudomonas aeruginosa lung infectionAnti-phage antibodiesImmune responseStandard-of-care antibioticsInvasive routes of administrationPhage-neutralizing antibodiesBacterial loadBacterial lung infectionsCystic Fibrosis FoundationNo adverse eventsRoute of administrationPhage preparationsEmergence of antibodiesPhage detectionAntibiotic susceptibilityPhageStaphylococcus aureusBacterial eradication
2022
Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter.
Winzig F, Gandhi S, Lee A, Würstle S, Stanley G, Capuano I, Neuringer I, Koff J, Turner P, Chan B. Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter. The Yale Journal Of Biology And Medicine 2022, 95: 413-427. PMID: 36568830, PMCID: PMC9765334.Peer-Reviewed Original ResearchConceptsCF patientsCystic fibrosisChronic pulmonary infectionGlobal public health threatBacterial lung infectionsChallenging clinical problemPublic health threatChronic bacterial lung infectionsPulmonary infectionRespiratory statusLung infectionClinical problemBacteriophage therapyInfectionAntimicrobial-resistant bacteriaTherapyHealth threatPhage therapyPatientsAMR infectionsResistant bacteriaLytic bacteriophagesPossible benefitsChemical antibioticsCurrent study